Nautilus Biotechnology, Inc. (NAUT) is a cutting-edge biotechnology company pioneering a single-molecule protein analysis platform. The company, based in Seattle, Washington, was founded by Dr. Sina Bari, a medical doctor and physicist, and Parag Mallick, an Associate Professor at Stanford University, in 2016.
The ambitious goal of the company is to decipher the human proteome, a set of all proteins in the human body, to unlock new knowledge about health and disease. Our understanding of DNA and genes has significantly increased over the past few decades, thanks to advancements in sequencing techniques. However, the world of proteins – the building blocks that genes instruct to make – remains relatively uncharted due to technological limitations. Nautilus Biotechnology intends to revolutionize this field.
Nautilus employs a combination of machine learning, biochemistry, advanced analytics, and high-throughput DNA sequencing to create a new standard for assessing biological samples. Their unified, high-throughput platform seeks to provide highly sensitive and accurate data, enabling a deeper and more comprehensive understanding of the proteome.
The company's proprietary technology has the potential to transform protein analysis, creating value in a range of industries, including drug discovery and development, diagnostics, and basic research. Understanding the proteome can help identify new drug targets, validate existing ones, identify biomarkers for therapy selection and development, monitor disease progression and treatment response, and advance our understanding of complex diseases.
The work of Nautilus Biotechnology is essential in the biotechnology and healthcare industries since better understanding of proteins can lead to advancements in treating diseases such as cancer, neurodegenerative disorders, and metabolic diseases. In February 2021, Nautilus announced a merger with Arya Sciences Acquisition Corp III, a special purpose acquisition company (SPAC), to become a publicly traded company on the Nasdaq exchange.
Nautilus Biotechnology, Inc. is a progressive company operating at the intersection of technology and biology. Through the development of their single-molecule protein analysis platform, they seek to enable a new era in quantitative biology to fuel future discovery, measurement, and ultimately improve human health.